| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLES |
Departments of Molecular Genetics (N.A.E., J.E.A., J.M., D.J.B.), Gene Expression Sciences (A.M.S., S.G.), and Cardiovascular Pharmacology (J.D., N.A.), SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406
Address all correspondence and requests for reprints to: Dr. Nabil A. Elshourbagy, Departments of Molecular Genetics, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406.
| Abstract |
|---|
|
|
|---|
-thio)-triphosphate. In functional studies, CGRP
stimulated the activation of adenylyl cyclase with an EC50
of 2.5 nM. The linear analog of CGRP, diacetoamidomethyl
cysteine CGRP, did not affect adenylyl cyclase activity on its own or
in the presence of CGRP. Furthermore, the CGRP receptor antagonists,
CGRP-(837)
, inhibited the CGRP-mediated response in a competitive
manner. Collectively, the binding and functional data demonstrate that
we have cloned a porcine CGRP type 1 receptor. The availability of the
CGRP-R complementary DNA will allow us to examine its participation in
pathophysiological processes. | Introduction |
|---|
|
|
|---|
- and ß-forms that vary by one
and three amino acids in the rat and human, respectively. CGRP
and
CGRPß display similar biological properties. When released from the
cell, CGRP initiates its biological responses by binding to specific
cell surface receptors that are predominantly coupled to the activation
of adenylyl cyclase (3, 4). CGRP receptors (CGRP-Rs) have been
identified and pharmacologically evaluated in several tissues and
cells, including those of brain, cardiovascular, endothelial, and
smooth muscle origin (2). Based on pharmacological properties, these
receptors are divided into at least two subtypes, denoted
CGRP1 and CGRP2 [according to the
classification of Dennis and Quirion (57)]. Human (h)
CGRP-(837)
, a fragment of CGRP that lacks seven N-terminal amino
acid residues, is a selective antagonist of CGRP1-Rs,
whereas the linear analog of CGRP, diacetoamidomethyl cysteine CGRP
([Cys(ACM)2,7]CGRP), is a selective agonist of CGRP2-Rs
(6). We recently reported the cloning and characterization of
complementary DNA (cDNA) encoding hCGRP-R type 1 (8, 9). Stable
expression of this cDNA in human embryonic kidney (HEK-293) cells
produced specific, high affinity binding sites for CGRP that displayed
pharmacological and functional properties very similar to those of
native CGRP1-R. Exposure of these cells to CGRP resulted in
an increase in cAMP production, which was inhibited in a competitive
manner by CGRP1-R antagonist hCGRP-(837)
. We report here the cloning of a cDNA encoding the porcine CGRP-R that shares 93% protein sequence identity with the hCGRP-R. Binding and functional studies confirm that the cloned receptor is the porcine ortholog of hCGRP1-R.
| Materials and Methods |
|---|
|
|
|---|
(SA,
2000 Ci/mmol) was obtained from Amersham (Chicago, IL). hCGRP
,
hCGRP-(837)
, human adrenomedullin (ADM), salmon calcitonin, human
calcitonin, endothelin, and porcine vasoactive intestinal peptide were
purchased from Bachem Bioscience, Inc. (King of Prussia, PA).
hCGRP-(937)
, hCGRP-(1037)
, and hCGRP-(1137)
were
synthesized at SmithKline Beecham Pharmaceuticals (King of Prussia.
PA). The BCA (bicinchoninic acid) protein assay kit was obtained from
Pierce Chemical Co. (Rockford, IL). All other reagents were obtained
from Sigma Chemical Co. (St. Louis, MO).
Construction and screening of the cDNA libraries
A porcine lung cDNA library constructed in a
ZAP express
vector (10) was screened by hybridization using a
32P-labeled human CGRP cDNA-coding sequence as a probe in
20% formamide, 5 x SSC (SSC is 150 mM NaCl and 15
mM sodium citrate), 5 x Denhardts solution, 0.1%
SDS, and 0.2 mg/ml Escherichia coli transfer RNA at 42 C
(11). Filters were finally washed with 2 x SSC-0.1% SDS at 42 C.
Several positive recombinant clones were isolated and characterized.
Preliminary sequence analysis showed that six of these clones encoded
the porcine CGRP-R.
Nucleotide sequence analysis
Both strands of the cDNA insert encoding the porcine CGRP-R were
sequenced using a modification of the dideoxy chain termination method
(12) using the Sequenase II kit (U.S. Biochemical Corp., Cleveland,
OH). The WI Genetics Computer Group Software package (13) was used to
assemble composite sequences from the various fragments and for
sequence analysis.
RNA blot analysis
For Northern analysis, polyadenylated RNA was isolated from
various porcine tissues using the guanidinium thiocyanate acid-phenol
method (14). One microgram of each RNA was fractionated on 1%
agarose-formaldehyde gels (15) and transferred to nitrocellulose
membranes. Hybridizations were performed at 42 C in 50% formamide, 5
x SSPE (0.75 M NaCl, 0.05 M NaH2
PO4, 0.06 M EDTA), 5 x
Denhardts reagent (0.1% Ficoll, 0.1% polyvinylpyrrolidone, 0.1%
BSA), 0.1% SDS, and 100 µg/ml yeast transfer RNA (16) using
32P-labeled porcine CGRP receptor cDNA insert. The
membranes were finally washed with 0.1 x SSPE-0.1% SDS at 50 C
and exposed to x-ray film for 4 days at -70 C.
Stable expression of the porcine CGRP-R
A fragment containing the entire porcine CGRP-R cDNA (coding
sequences only) was subcloned into the mammalian expression vector pCDN
(17). Human embryonic kidney cells (HEK-293) were plated at 3 x
105 cells/well in a six-well tissue culture plate in
Eagles MEM supplemented with 10% FBS. The next day, cells were
transfected in serum-free Eagles MEM with 2 µg plasmid DNA encoding
the porcine CGRP-R gene using 5 µl Lipofectamine (Life Technologies,
Gaithersburg, MD) following the manufacturers protocol. After 48
h, cells were diluted, transferred to 100-mm dishes, and selected in
0.4 mg/ml geneticin (Life Technologies) until visible foci formed
(
15 days). Colonies were picked, expanded, and tested for the
expression of porcine CGRP-R by cAMP production. One of the six stable
clones was characterized in detail. To confirm that the transfected
HEK-293 clonal cell line expressed the porcine CGRP-R, oligonucleotide
primers were synthesized corresponding to the amino-terminal (ATG GAG
AAA AAG TAT ATC CTG TAT TTT C) and carboxyl-terminal (TTC CAT TTA AGT
GTT CGC TTG GAT AG), and RT-PCR was used to clone the porcine CGRP-R
cDNA from the HEK-293/CGRP-R transfected cell mRNA. As determined by
DNA sequence analysis, the porcine CGRP-R was indeed expressed in
transfected, but not vector-transfected, cells.
Membrane preparation
Cells were detached from culture flasks (T-150, Falcon) with 1
mM EDTA in
Ca2+/Mg2+-free Dulbeccos PBS,
washed by centrifugation at 300 x g, and stored as
frozen pellet. Crude membranes were prepared as we described previously
for porcine lung membranes (18). In brief, the cells were suspended in
ice-cold buffer containing 10 mM Tris-HCl (pH 7.4), 5
mM Na-EDTA, 0.1 mM
phenylmethylsulfonylfluoride, 1.0 mg/ml bacitracin, and 0.1 mg/ml
aprotinin (buffer A) and homogenized using a Dounce homogenizer (Kontes
Co., Vineland, NJ). The homogenates were centrifuged at 47,000 x
g for 20 min at 4 C; the membrane pellets were washed twice
by centrifugation in buffer containing 20 mM Na-HEPES (pH
7.4), 5 mM MgCl2, 2 mM Na-EGTA, and
0.1 mg/ml bacitracin (buffer B); and the membranes were resuspended in
the same buffer at 5 mg/ml and stored frozen at -70 C. The protein
concentration was measured by the Pierce BCA method using BSA as a
standard.
Radioligand binding assays
Radioligand binding assays were performed as described
previously (19). In saturation binding studies, increasing
concentrations of [125I]hCGRP
were added and incubated
in a total volume of 500 µl (50100 µg membrane proteins/ml) for
30 min at 25 C. Nonspecific binding was determined in the presence of 1
µM unlabeled hCGRP
. In competition binding studies,
the membranes (50100 µg membrane protein/ml) were incubated with
increasing concentrations (1 pM to 1 µM) of
competing ligand and 125150 pM
[125I]hCGRP
for 30 min at 25 C. The incubations were
terminated by the addition of 2 ml cold wash buffer (0.9% NaCl)
followed by rapid filtration over Skatron filtermates presoaked in
0.2% polyethyleneimine using a Skatron cell harvester (Skatron
Instruments, Norway). All binding assays were performed in duplicate,
and each experiment was repeated three or four times. Analysis of all
binding data (determination of Kd, binding capacity, and
Ki values) was performed by computer-assisted
nonlinear least square fitting using GraphPad PRIZM (GraphPad Software,
San Diego, CA).
Adenylyl cyclase activity
Adenylyl cyclase activity was measured in triplicate as the rate
of conversion of [
-32P]ATP to [32P]cAMP,
as previously described (19). Membranes (4060 µg protein) were
incubated in triplicate in buffer containing 50 mM Tris-HCl
(pH 7.4), 10 mM MgCl2, 1.2 mM ATP,
1.0 µCi [
-32P]ATP, 0.1 mM cAMP, 2.8
mM phosphoenolpyruvate, and 5.2 µg/ml myokinase in a
final volume of 100 µl for 20 min at 30 C. The reactions were stopped
with 1 ml of a solution containing cAMP (0.28 mM), ATP
(0.33 mM), and 22,000 dpm [3H]cAMP.
[32P]cAMP was separated using sequential chromatography
(Dowex and alumina columns) (20). Adenylyl cyclase activities were
determined in the absence (basal) or presence of various concentrations
of hCGRP
(1 pM to 1 µM). The additive
effect of the peptides on adenylyl cyclase was also determined.
Forskolin (10 µM) was used as a positive control for the
activation of adenylyl cyclase. The effects of various concentrations
of hCGRP-(837)
, a CGRP-R antagonist, on hCGRP
-mediated
activation of adenylyl cyclase were also determined. Intracellular
CGRP-mediated cAMP determinations were performed after seeding the
stably transfected cells into six-well plates, as described previously
(8).
| Results and Discussion |
|---|
|
|
|---|
|
mRNA size and tissue distribution
Northern blot hybridization analysis using the full-length cDNA as
a hybridization probe revealed a mRNA species approximately 5.4
kilobases in size exclusively in the lung (Fig. 2
). The porcine CGRP-R mRNA was not
detected in the heart or cerebellum, which is consistent with the
expression pattern observed for hCGRP-R (8).
|
|
and hCGRPß were
equipotent in the competition binding assay. The relative order of
potencies for the C-terminal fragments of CGRP was CGRP-(837)
>
hCGRP-(937)
> hCGRP-(1037)
> CGRP-(1137)
. This rank
order correlates well with that observed for these fragments in rat
brain (7). hCGRP-(837)
and hCGRP-(937)
displayed 7- and
14-fold weaker affinities, respectively, than the native peptide,
whereas CGRP-(1037)
and CGRP-(1137)
demonstrated 175- and
275- fold weaker affinities, respectively, than hCGRP. The linear
peptide, [Cys(ACM)2,7]CGRP, and ADM were 30- and 200-fold weaker,
respectively, than the native peptide. Salmon calcitonin displayed
negligible affinity for this CGRP-R. Unrelated peptides such as
angiotensin II and endothelin I did not compete for binding (Fig. 4B
. Competition curves obtained for CGRP analogs against
[125I]CGRP-(837)
binding were similar to those
obtained with [125I]CGRP
binding to these membranes
(data not shown).
|
|
binding has been described in liver,
skeletal muscle, and guinea pig lung, rat cerebellum, and SK-N-MC cells
(24, 25).
To assess CGRP-R-G protein interactions in HEK-293 cells expressing the
porcine CGRP-R, competition binding experiments were performed with
[125I]CGRP-(837) and unlabeled CGRP in the presence and
absence of a nonhydrolyzable GTP analog, guanosine 5'
(
-thio)-triphosphate (GTP
S). As shown in Fig. 5
, GTP
S shifted the CGRP competition
curve to the right, resulting in an increase in IC50 value
from 0.48 to 3.5 nM (n = 2). Analysis of the data
showed that competition data by CGRP in both the absence and presence
of GTP
S were best fit by a model described by one class of binding
sites with Ki values of 0.21 and 1.5
nM, respectively. These results show that binding of
agonists to recombinant porcine CGRP-R was regulated by guanine
nucleotides, presumably by an interaction with a guanine
nucleotide-binding proteins.
|
, CGRPß also stimulated adenylyl cyclase
activity, with an EC50 of 0.4 ± 0.12 nM.
The linear CGRP peptide, [Cys(ACM)2,7]CGRP; ADM; and human and salmon
calcitonin failed to stimulate adenylyl cyclase activity significantly
in the porcine CGRP-R-transfected HEK-293 cell membranes (data not
shown). In the untransfected HEK-293 cell membranes, CGRP
, CGRPß,
ADM, and calcitonin showed no significant activation of adenylyl
cyclase activity. The CGRP-R antagonist, CGRP-(837)
by itself has
little effect (30% over basal at 100 nM) on the activation
of adenylyl cyclase activity in the HEK-293 cell membranes expressing
the recombinant porcine CGRP-R. However, CGRP-(837)
was effective
in inhibiting CGRP-mediated adenylyl cyclase activity in these
membranes, with an IC50 of 14.5 ± 2 nM.
As shown in Fig. 8
at
various concentrations induced significant parallel rightward shifts of
the concentration-response curves of CGRP-mediated activation of
adenylyl cyclase activity. The parallel rightward shift of CGRP
dose-response curves and the lack of effect on the maximum response by
this antagonist suggest that this is a competitive antagonist.
|
|
|
, inhibits CGRP-mediated
functional response in a competitive manner. Thirdly, the
CGRP-2-R-selective agonists, Cys[ACM-CGRP] did not display any
response. These data collectively suggest that the recombinant porcine
CGRP-R is a type 1 receptor. The availability of the
CGRP1-R will facilitate investigation of the potential
roles of CGRP and its possible participation in physiological and
pathophysiological processes.
| Acknowledgments |
|---|
| Footnotes |
|---|
Received May 20, 1997.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
R. T. Dackor, K. Fritz-Six, W. P. Dunworth, C. L. Gibbons, O. Smithies, and K. M. Caron Hydrops fetalis, cardiovascular defects, and embryonic lethality in mice lacking the calcitonin receptor-like receptor gene. Mol. Cell. Biol., April 1, 2006; 26(7): 2511 - 2518. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. D. Brain and A. D. Grant Vascular Actions of Calcitonin Gene-Related Peptide and Adrenomedullin Physiol Rev, July 1, 2004; 84(3): 903 - 934. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Poyner, P. M. Sexton, I. Marshall, D. M. Smith, R. Quirion, W. Born, R. Muff, J. A. Fischer, and S. M. Foord International Union of Pharmacology. XXXII. The Mammalian Calcitonin Gene-Related Peptides, Adrenomedullin, Amylin, and Calcitonin Receptors Pharmacol. Rev., June 1, 2002; 54(2): 233 - 246. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. R. Rorabaugh, M. A. Scofield, D. D. Smith, W. B. Jeffries, and P. W. Abel Functional Calcitonin Gene-Related Peptide Subtype 2 Receptors in Porcine Coronary Arteries Are Identified as Calcitonin Gene-Related Peptide Subtype 1 Receptors by Radioligand Binding and Reverse Transcription-Polymerase Chain Reaction J. Pharmacol. Exp. Ther., December 1, 2001; 299(3): 1086 - 1094. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Aiyar, R. A. Daines, J. Disa, P. A. Chambers, C. F. Sauermelch, M.-J. Quiniou, N. Khandoudi, B. Gout, S. A. Douglas, and R. N. Willette Pharmacology of SB-273779, a Nonpeptide Calcitonin Gene-Related Peptide 1 Receptor Antagonist J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 768 - 775. [Abstract] [Full Text] |
||||
![]() |
J. P. Hinson, S. Kapas, and D. M. Smith Adrenomedullin, a Multifunctional Regulatory Peptide Endocr. Rev., April 1, 2000; 21(2): 138 - 167. [Abstract] [Full Text] |
||||
![]() |
W. Nowak, N. Parameswaran, C. S. Hall, N. Aiyar, H. V. Sparks, and W. S. Spielman Novel regulation of adrenomedullin receptor by PDGF: role of receptor activity modifying protein-3 Am J Physiol Cell Physiol, June 1, 2002; 282(6): C1322 - C1331. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |